|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: EMA (2007), FDA (2008)) |
IUPAC Name ![]() |
| [2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 8068 | fesoterodine |
Synonyms ![]() |
| SPM-8272 |
| SPM-907 |
| Toviaz® |
Database Links ![]() |
|
| CAS Registry No. | 286930-03-8 |
| ChEMBL Ligand | CHEMBL1201764 |
| DrugBank Ligand | DB06702 |
| PubChem CID | 6918558 |
| Search Google for chemical match using the InChIKey | DCCSDBARQIPTGU-HSZRJFAPSA-N |
| Search Google for chemicals with the same backbone | DCCSDBARQIPTGU |
| Search PubMed clinical trials | fesoterodine |
| Search PubMed titles | fesoterodine |
| Search PubMed titles/abstracts | fesoterodine |
| Wikipedia | Fesoterodine |
| Comments |
| The marketed formulation contains the fumarate compound (PubChem CID 9849808). Fesoterodine is an antimuscarinic prodrug, with the active metabolite being 5-hydroxymethyl tolterodine (5-HMT, PubChem CID 9819382). |